Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis
Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis have?
Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis has 8 citations in the OpenAlex counts ScholarIQ stores.
When was Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis published?
Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis has 2024 year in the ScholarIQ index.
What is the open-access status of Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis?
Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis has hybrid oa status in the ScholarIQ index.
What is the DOI of Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis?
The DOI for Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis is on the source record.
What is the PMID of Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis?
The PMID for Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis is on the source record.
What is the OpenAlex record for Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis?
The OpenAlex for Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis is on the source record.